Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects

Summary

The goal of this clinical trial is to learn about how certain medications used to treat insomnia (e.g., Lemborexant) impact sleep, mood, and behavior in men and women with Opioid Use Disorder who are taking prescribed buprenorphine. The main questions it aims to answer are:

1. What is the effect of the study drug (lemborexant) on sleep outcomes?
2. What is the effect of the study drug (lemborexant) on impulsive behavior (as measured by computer test performance)?
3. What is the effect of the study drug (lemborexant) on mood and other behavior?

Researchers will compare lemborexant to placebo (e.g., sugar pill) to see if participants assigned to 8 weeks of treatment with lemborexant have greater improvements on the measures listed above.

Participants will take the study medication (or placebo) each night for 8 weeks and be asked to come for a total of 23 study visits. Most of these visits will be very short (15-30 minutes). The longer visits will include the screening visit (about 2-3 hrs), baseline visit (about 2.5 hrs), and the post-medication visit (about 2 hrs). Study visits will include things like taking surveys about sleep, drug use, and mood, completing urine drug testing, checking vital signs (e.g., blood pressure), and completing interviews with the study staff. Participants will also be asked to provide two blood samples (one during screening and one after taking the medication). For three two-week periods, participants will be asked to wear a watch to track sleep at home, and to keep a log of sleep and wake times.

Conditions

• Opioid Use Disorder
• Opioid Use
• Insomnia
• Orexin Antagonist

Interventions

DRUG

Placebo

Subjects who are randomized to placebo will receive identical capsules to the study drug. During the 8-week intervention phase, participants will be instructed to take one capsule daily, approximately 5-30 minutes before going to bed

DRUG

Lemborexant 10 MG

During the 8-week intervention phase, participants will be instructed to take one capsule daily, approximately 5-30 minutes before going to bed

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• Virginia Commonwealth University

  lead OTHER

Principal Investigators

• Caitlin E Martin, MD · Virginia Commonwealth University Institute for Drug and Alcohol Studies

Study Design

Allocation

RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-05-27

Primary Completion

2029-07-30

Completion

2029-07-30

FDA Drug

Yes

Countries

• United States

Study Locations